FRA:ZEG • GB0009895292
We assign a fundamental rating of 5 out of 10 to ZEG. ZEG was compared to 52 industry peers in the Pharmaceuticals industry. While ZEG belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. ZEG has a decent growth rate and is not valued too expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.96% | ||
| ROE | 21.01% | ||
| ROIC | 13.63% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.86% | ||
| PM (TTM) | 17.41% | ||
| GM | 81.31% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.42 | ||
| Altman-Z | 3.77 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.72 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.53 | ||
| Fwd PE | 18.05 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.09 | ||
| EV/EBITDA | 16.14 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.64% |
FRA:ZEG (2/5/2026, 7:00:00 PM)
160.7
+0.95 (+0.59%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.64% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.53 | ||
| Fwd PE | 18.05 | ||
| P/S | 5.03 | ||
| P/FCF | 34.09 | ||
| P/OCF | 20.28 | ||
| P/B | 6.07 | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.14 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.96% | ||
| ROE | 21.01% | ||
| ROCE | 16.8% | ||
| ROIC | 13.63% | ||
| ROICexc | 14.63% | ||
| ROICexgc | 59.47% | ||
| OM | 23.86% | ||
| PM (TTM) | 17.41% | ||
| GM | 81.31% | ||
| FCFM | 14.76% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.42 | ||
| Debt/EBITDA | 1.36 | ||
| Cap/Depr | 103% | ||
| Cap/Sales | 10.05% | ||
| Interest Coverage | 10.65 | ||
| Cash Conversion | 73.79% | ||
| Profit Quality | 84.79% | ||
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 3.77 |
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 23.53 and the Price/Book (PB) ratio is 6.07.
The Earnings per Share (EPS) of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 30.41% in the next year.